Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era

(2022) Laura Kalfeist et al.   Cells

Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors

(2021) Marcus Skribek et al.   EUROPEAN JOURNAL OF CANCER

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020

(2021) Wei Cao et al.   CHINESE MEDICAL JOURNAL

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

(2021) Alessio Cortellini et al.   Journal for ImmunoTherapy of Cancer

Impact of corticosteroid use on outcomes of non–small‐cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis

(2021) Hongchuan Zhang et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Lung cancer

(2021) Alesha A Thai et al.   LANCET

Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment

(2021) Ying Wang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: Real world experience in Argentina

(2020) Claudio Martin et al.   Clinical Lung Cancer

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

(2020) MARTIN SVATON et al.   ANTICANCER RESEARCH

Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer

(2020) Ou Yamaguchi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

(2020) Francesco Facchinetti et al.   EUROPEAN JOURNAL OF CANCER

Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases

(2020) Takehiro Tozuka et al.   Thoracic Cancer

Steroid Use Independently Predicts Poor Outcome In Patients With Advanced Nsclc And High Pd-L1 Expression Receiving First-Line Pembrolizumab Monotherapy

(2020) Giannis Mountzios et al.   Clinical Lung Cancer

Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%

(2020) Giulio Metro et al.   JOURNAL OF IMMUNOTHERAPY

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy

(2020) Leilei Ai et al.   Drug Design Development and Therapy

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)

(2020) Andrea De Giglio et al.   Cancers

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents

(2020) Mariona Riudavets et al.   Frontiers in Oncology

Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers

(2020) Riccardo Lobefaro et al.   LUNG CANCER

Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

(2019) Lizza E.L. Hendriks et al.   Journal of Thoracic Oncology

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)

(2019) Motohiro Tamiya et al.   INVESTIGATIONAL NEW DRUGS

Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications

(2019) Biagio Ricciuti et al.   JOURNAL OF CLINICAL ONCOLOGY

Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells

(2019) Natsumi Maeda et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?

(2019) Bellesoeur et al.   Cancers

Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status

(2019) Yuichi Adachi et al.   Cancer Medicine

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Brief report: Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab

(2018) Susan Combs Scott et al.   Journal of Thoracic Oncology

Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab

(2018) Coraline Dumenil et al.   PLoS One

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

(2018) Kathryn C. Arbour et al.   JOURNAL OF CLINICAL ONCOLOGY

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

(2016) F. Roila et al.   ANNALS OF ONCOLOGY

Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers

(2013) Lisa Hartling et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Dyspnea in Palliative Care: Expanding the Role of Corticosteroids

(2012) Richard J. Lin et al.   JOURNAL OF PALLIATIVE MEDICINE

How to obtain the confidence interval from a P value

(2011) D. G. Altman et al.   BMJ-British Medical Journal

The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline

(2009) Timothy C. Ryken et al.   JOURNAL OF NEURO-ONCOLOGY